Inducing Pro-Inflammatory Macrophage Activation State by Introducing IKK2 Gene Into New CAR-M Construct

Department

University of Utah, Department of Biochemistry, 201 Presidents' Cir, Salt Lake City, UT 84112

Document Type

Poster

Publication Date

4-17-2026

Abstract

CAR-Ms (Chimeric Antigen Receptor-Macrophages) are a type of immunotherapy that is a genetically engineered construct inputted into a macrophage to target tumor cells and control tumor growth. This technology is being used to study efficacy in glioblastoma because a macrophage can perform phagocytosis, eating into a physical tumor. Furthermore, current glioblastoma therapy leaves patients with a poor prognosis of under two years after treatment. The purpose of this project is to increase CAR-M activation by modifying the intracellular domain of the Roh-Johnson lab’s CAR-M, which includes a construct to target cells that express NG2, which is expressed on glioblastoma cells. The test is to determine how tumor growth is controlled by adding IKK2, a gene that causes downstream signaling to promote inflammation.

This document is currently not available here.

Share

COinS